These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 16804926

  • 1. The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894.
    Beer TM, Tangen CM, Bland LB, Hussain M, Goldman BH, DeLoughery TG, Crawford ED, Southwest Oncology Group Study.
    Cancer; 2006 Aug 01; 107(3):489-96. PubMed ID: 16804926
    [Abstract] [Full Text] [Related]

  • 2. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
    D'Amico AV, Saegaert T, Chen MH, Renshaw AA, George D, Oh W, Kantoff PW.
    Cancer; 2002 Jul 15; 95(2):275-80. PubMed ID: 12124826
    [Abstract] [Full Text] [Related]

  • 3. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA.
    Cancer; 2009 Oct 01; 115(19):4470-6. PubMed ID: 19637339
    [Abstract] [Full Text] [Related]

  • 4. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study.
    Lavey RS, Liu PY, Greer BE, Robinson WR, Chang PC, Wynn RB, Conrad ME, Jiang C, Markman M, Alberts DS.
    Gynecol Oncol; 2004 Oct 01; 95(1):145-51. PubMed ID: 15385124
    [Abstract] [Full Text] [Related]

  • 5. Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
    Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN.
    Circulation; 2005 Aug 23; 112(8):1121-7. PubMed ID: 16103233
    [Abstract] [Full Text] [Related]

  • 6. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.
    Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, Klein EA, Crawford ED, Southwest Oncology Group.
    J Urol; 2007 Nov 23; 178(5):1946-51; discussion 1951. PubMed ID: 17868721
    [Abstract] [Full Text] [Related]

  • 7. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
    Curtis KK, Adam TJ, Chen SC, Pruthi RK, Gornet MK.
    Aging Male; 2008 Dec 23; 11(4):157-61. PubMed ID: 18937151
    [Abstract] [Full Text] [Related]

  • 8. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).
    Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D, Southwest Oncology Group Trial 9346 (INT-0162).
    J Clin Oncol; 2006 Aug 20; 24(24):3984-90. PubMed ID: 16921051
    [Abstract] [Full Text] [Related]

  • 9. Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer.
    Park SH, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH.
    Cancer Chemother Pharmacol; 2006 Jan 20; 57(1):91-6. PubMed ID: 16088407
    [Abstract] [Full Text] [Related]

  • 10. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
    Yashi M, Nukui A, Kurokawa S, Ochi M, Ishikawa S, Goto K, Kobayashi Y, Muraishi O, Tokue A.
    Prostate; 2003 Sep 01; 56(4):305-12. PubMed ID: 12858359
    [Abstract] [Full Text] [Related]

  • 11. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
    DiBlasio CJ, Malcolm JB, Hammett J, Wan JY, Aleman MA, Patterson AL, Wake RW, Derweesh IH.
    BJU Int; 2009 Nov 01; 104(9):1208-14. PubMed ID: 19388987
    [Abstract] [Full Text] [Related]

  • 12. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU.
    J Clin Oncol; 2008 Feb 01; 26(4):592-8. PubMed ID: 18235117
    [Abstract] [Full Text] [Related]

  • 13. Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.
    Bogdanos J, Karamanolakis D, Milathianakis C, Repousis P, Tsintavis A, Koutsilieris M.
    Anticancer Res; 2003 Feb 01; 23(2C):1757-62. PubMed ID: 12820454
    [Abstract] [Full Text] [Related]

  • 14. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
    Okegawa T, Nutahara K, Higashihara E.
    J Urol; 2008 Oct 01; 180(4):1342-7. PubMed ID: 18707699
    [Abstract] [Full Text] [Related]

  • 15. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
    George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW.
    Clin Cancer Res; 2005 Mar 01; 11(5):1815-20. PubMed ID: 15756004
    [Abstract] [Full Text] [Related]

  • 16. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 01; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 17. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR.
    J Natl Cancer Inst; 2007 Oct 17; 99(20):1516-24. PubMed ID: 17925537
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
    Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.
    Cancer; 2008 Mar 15; 112(6):1247-53. PubMed ID: 18293426
    [Abstract] [Full Text] [Related]

  • 19. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
    Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML.
    J Urol; 2008 May 15; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
    [Abstract] [Full Text] [Related]

  • 20. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
    Lacson E, Ofsthun N, Lazarus JM.
    Am J Kidney Dis; 2003 Jan 15; 41(1):111-24. PubMed ID: 12500228
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.